GlobeNewswire by notified

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate

Share

COPENHAGEN, Denmark, May 5, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate. Data from subjects, who were previously vaccinated with approved mRNA or adenoviral vaccines, demonstrated that vaccination with ABNCoV2 induced a significant boost to the neutralizing antibodies against the Omicron variant in the majority of subjects with a fold increase in the same range as previously reported for the original Wuhan SARS-CoV2 variant. While the neutralizing antibody titers against Omicron were the lowest when compared to all other variants previously reported (Wuhan, Alpha, Beta and Delta) they were boosted to levels associated with a high level of protection1 across both dose groups, 50μg and 100μg.

These data follow the announcement of topline results from the Phase 2 trial in December 2021 and February 2022, demonstrating that a single vaccination with 50μg or 100μg ABNCoV2 can boost neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV21, irrespective of type of vaccine previously received (mRNA or adenovirus-based), or the initial level of neutralizing antibody titers before booster vaccination with ABNCoV2.

Paul Chaplin, President and CEO of Bavarian Nordic, commented: “We now have demonstrated a large range of immune responses against different variants of concern, including Omicron. This encourages us to continue to rapidly initiate our phase 3 study and subsequently submit this vaccine for licensure.”

Supported by the Danish State, Bavarian Nordic plans to initiate soon a Phase 3 program of ABNCoV2. The program will include approximately 4,000 seropositive subjects who will receive a booster vaccination with 100 μg ABNCoV2 or an mRNA-based vaccine, aiming to demonstrate non-inferiority of ABNCoV2 to the licensed mRNA vaccine.

About ABNCoV2
ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark using their proprietary capsid virus like particle (cVLP) technology. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. Results from a Phase 2 trial has confirmed the ability of ABNCoV2 to significantly boost antibody titers as previously demonstrated in preclinical and Phase 1 clinical trials, and also confirm the potential of ABNCoV2 to boost antibody titers against SARS-CoV2 variants of concern.

About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company listed on the NASDAQ Copenhagen exchange and with operations in Europe and the USA. Our mission is to save and improve lives by unlocking the power of the immune system and we aspire to become one of the largest pure play vaccine companies by developing innovative life-saving vaccines, excelling in commercialization and being a best-in-class vaccine manufacturer. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next-generation COVID-19 vaccine and a vaccine against respiratory syncytial virus (RSV), which are both entering Phase 3 clinical trials in 2022. For more information visit www.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

Company Announcement no. 14 / 2022




1 P. B. Gilbert et al., Science 10.1126/science.abm3425 (2021)


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nextensa NV/SA : Shares repurchase26.5.2022 17:40:00 CEST | Press release

PRESS RELEASE REGULATED INFORMATION Brussels, 26 May 2022 – 5.40 PM CEST Nextensa NV/SA : Shares repurchase In accordance with article 8:4 of the Royal Decree of 29 April 2019 in execution of the Belgian Code of Companies and Associations, Nextensa announces that in the period between May 19, 2022 and May 25, 2022 included it has repurchased 1,889 treasury shares on Euronext Brussels as part of its announced share buy-back program1. The shares were repurchased at an average price (rounded) of € 68.00 per share. This share repurchase transaction was carried out to cover the purchase plans for the benefit of the executive management of Nextensa, and this within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders on 19 July 2021. Detailed operations per day DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)19/05/202245067.8667.7067.9030,535.0020/05/202245068.4868.4068.9030,8

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons26.5.2022 15:00:33 CEST | Press release

26 May 2022 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 24 May 2022, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 3,130 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 48,175 shares, representing 0.13% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Paul Meader 2) Sarah Kingwell 2 Reason for the notification a) Position/status 1) Director and Chairman 2) PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platfor

Mandalay Resources Corporation tillkännager resultatet av årsstämman26.5.2022 14:41:34 CEST | Pressemelding

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att tillkännage resultaten från årsstämman (”mötet”) som hölls virtuellt idag. Alla resolutioner som presenterades vid mötet godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 67,63 % av de totalt utestående aktierna på avstämningsdagen. Val av styrelseledamöter Antalet styrelseledamöter var oförändrat med sju ledamöter och var och en av de sju nominerade som fanns listade i bolagsledningens informationsutskick från den 14 april 2022 återvaldes till bolagsstyrelsen. Abraham Jonker fortsätter som oberoende samordnande ledamot och Bradford Mills fortsätter som ordförande. Resultaten av rösterna genom ombud anges nedan. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94533,7750.055Dominic Duff

Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release

Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release

– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a